San Diego-based mostly Viking Therapeutics marked by itself as a serious competitor in the weight loss drug marketplace in February just after revealing promising details from the mid-phase demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection As well as in March